Even if previous research suggested that SGLT2 inhibitors did not influence the number of EPCs [128], a recent study revealed that canagliflozin increased the CXCR4 receptor expression and migratory profile of EPCs in patients with diabetes [129]. The gene discussed is SLC5A2; the disease is diabetes mellitus.